The inhibition of constitutive androstane receptor-mediated pathway enhances the effects of anticancer agents in ovarian cancer cells

Yan Wang, Hisashi Masuyama, Etsuko Nobumoto, Guangmei Zhang, Yuji Hiramatsu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background Ovarian cancer is commonly treated with anticancer agents; however, many tumors become resistant. Resistance is regulated, in part, by P-glycoprotein, which is encoded by the gene multiple drug resistance 1 (MDR1) and functions as a transmembrane efflux pump for the elimination of anticancer agents. Constitutive androstane receptor (CAR) is a nuclear receptor that regulates drug metabolism through control of MDR1 and other genes. Purpose We examined whether the inhibition of CAR-mediated pathway could influence the cytotoxicity of three anticancer drugs, cisplatin, paclitaxel, and arsenic trioxide, in ovarian cancer cells. Results We observed that the cell proliferation of several ovarian cell lines expressing CAR significantly increased when CITCO was combined with anticancer agents compared with any anticancer agent alone. The up-regulation of MDR1 and UGT1A1 by anticancer agents was further enhanced in the presence of CITCO. We confirmed that combining CITCO with anticancer agents induced significantly lower levels of apoptosis than those achieved with any single anticancer drug. CAR down-regulation by RNA interference caused a significant increase in cell growth inhibition and enhancement of apoptosis in the presence of anticancer agents. Combination of CITCO with any anticancer agents significantly enhanced CAR-mediated transcription compared with any anticancer agents alone and CAR down-regulation completely inhibited the transcription in the presence of CITCO and/or anticancer agents. Conclusion Inhibition of CAR pathway could be a novel therapeutic approach for the augmentation of sensitivity to anticancer agents, or to overcome resistance, in the treatment of ovarian cancer.

Original languageEnglish
Pages (from-to)356-366
Number of pages11
JournalBiochemical Pharmacology
Volume90
Issue number4
DOIs
Publication statusPublished - Aug 15 2014

Fingerprint

Antineoplastic Agents
Ovarian Neoplasms
Cells
Multiple Drug Resistance
Pharmaceutical Preparations
Transcription
constitutive androstane receptor
Down-Regulation
Genes
Apoptosis
Cell proliferation
Cell growth
P-Glycoprotein
Cytotoxicity
Cytoplasmic and Nuclear Receptors
RNA Interference
Paclitaxel
Metabolism
Cisplatin
Tumors

Keywords

  • Anticancer agents
  • Constitutive androstane receptor
  • Multiple drug resistance 1
  • Ovarian cancer
  • Uridine diphosphate-5′-glucuronosyltransferase 1A1

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

The inhibition of constitutive androstane receptor-mediated pathway enhances the effects of anticancer agents in ovarian cancer cells. / Wang, Yan; Masuyama, Hisashi; Nobumoto, Etsuko; Zhang, Guangmei; Hiramatsu, Yuji.

In: Biochemical Pharmacology, Vol. 90, No. 4, 15.08.2014, p. 356-366.

Research output: Contribution to journalArticle

@article{3a8ce91d5a7e4774891429f03f8dea7f,
title = "The inhibition of constitutive androstane receptor-mediated pathway enhances the effects of anticancer agents in ovarian cancer cells",
abstract = "Background Ovarian cancer is commonly treated with anticancer agents; however, many tumors become resistant. Resistance is regulated, in part, by P-glycoprotein, which is encoded by the gene multiple drug resistance 1 (MDR1) and functions as a transmembrane efflux pump for the elimination of anticancer agents. Constitutive androstane receptor (CAR) is a nuclear receptor that regulates drug metabolism through control of MDR1 and other genes. Purpose We examined whether the inhibition of CAR-mediated pathway could influence the cytotoxicity of three anticancer drugs, cisplatin, paclitaxel, and arsenic trioxide, in ovarian cancer cells. Results We observed that the cell proliferation of several ovarian cell lines expressing CAR significantly increased when CITCO was combined with anticancer agents compared with any anticancer agent alone. The up-regulation of MDR1 and UGT1A1 by anticancer agents was further enhanced in the presence of CITCO. We confirmed that combining CITCO with anticancer agents induced significantly lower levels of apoptosis than those achieved with any single anticancer drug. CAR down-regulation by RNA interference caused a significant increase in cell growth inhibition and enhancement of apoptosis in the presence of anticancer agents. Combination of CITCO with any anticancer agents significantly enhanced CAR-mediated transcription compared with any anticancer agents alone and CAR down-regulation completely inhibited the transcription in the presence of CITCO and/or anticancer agents. Conclusion Inhibition of CAR pathway could be a novel therapeutic approach for the augmentation of sensitivity to anticancer agents, or to overcome resistance, in the treatment of ovarian cancer.",
keywords = "Anticancer agents, Constitutive androstane receptor, Multiple drug resistance 1, Ovarian cancer, Uridine diphosphate-5′-glucuronosyltransferase 1A1",
author = "Yan Wang and Hisashi Masuyama and Etsuko Nobumoto and Guangmei Zhang and Yuji Hiramatsu",
year = "2014",
month = "8",
day = "15",
doi = "10.1016/j.bcp.2014.06.003",
language = "English",
volume = "90",
pages = "356--366",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - The inhibition of constitutive androstane receptor-mediated pathway enhances the effects of anticancer agents in ovarian cancer cells

AU - Wang, Yan

AU - Masuyama, Hisashi

AU - Nobumoto, Etsuko

AU - Zhang, Guangmei

AU - Hiramatsu, Yuji

PY - 2014/8/15

Y1 - 2014/8/15

N2 - Background Ovarian cancer is commonly treated with anticancer agents; however, many tumors become resistant. Resistance is regulated, in part, by P-glycoprotein, which is encoded by the gene multiple drug resistance 1 (MDR1) and functions as a transmembrane efflux pump for the elimination of anticancer agents. Constitutive androstane receptor (CAR) is a nuclear receptor that regulates drug metabolism through control of MDR1 and other genes. Purpose We examined whether the inhibition of CAR-mediated pathway could influence the cytotoxicity of three anticancer drugs, cisplatin, paclitaxel, and arsenic trioxide, in ovarian cancer cells. Results We observed that the cell proliferation of several ovarian cell lines expressing CAR significantly increased when CITCO was combined with anticancer agents compared with any anticancer agent alone. The up-regulation of MDR1 and UGT1A1 by anticancer agents was further enhanced in the presence of CITCO. We confirmed that combining CITCO with anticancer agents induced significantly lower levels of apoptosis than those achieved with any single anticancer drug. CAR down-regulation by RNA interference caused a significant increase in cell growth inhibition and enhancement of apoptosis in the presence of anticancer agents. Combination of CITCO with any anticancer agents significantly enhanced CAR-mediated transcription compared with any anticancer agents alone and CAR down-regulation completely inhibited the transcription in the presence of CITCO and/or anticancer agents. Conclusion Inhibition of CAR pathway could be a novel therapeutic approach for the augmentation of sensitivity to anticancer agents, or to overcome resistance, in the treatment of ovarian cancer.

AB - Background Ovarian cancer is commonly treated with anticancer agents; however, many tumors become resistant. Resistance is regulated, in part, by P-glycoprotein, which is encoded by the gene multiple drug resistance 1 (MDR1) and functions as a transmembrane efflux pump for the elimination of anticancer agents. Constitutive androstane receptor (CAR) is a nuclear receptor that regulates drug metabolism through control of MDR1 and other genes. Purpose We examined whether the inhibition of CAR-mediated pathway could influence the cytotoxicity of three anticancer drugs, cisplatin, paclitaxel, and arsenic trioxide, in ovarian cancer cells. Results We observed that the cell proliferation of several ovarian cell lines expressing CAR significantly increased when CITCO was combined with anticancer agents compared with any anticancer agent alone. The up-regulation of MDR1 and UGT1A1 by anticancer agents was further enhanced in the presence of CITCO. We confirmed that combining CITCO with anticancer agents induced significantly lower levels of apoptosis than those achieved with any single anticancer drug. CAR down-regulation by RNA interference caused a significant increase in cell growth inhibition and enhancement of apoptosis in the presence of anticancer agents. Combination of CITCO with any anticancer agents significantly enhanced CAR-mediated transcription compared with any anticancer agents alone and CAR down-regulation completely inhibited the transcription in the presence of CITCO and/or anticancer agents. Conclusion Inhibition of CAR pathway could be a novel therapeutic approach for the augmentation of sensitivity to anticancer agents, or to overcome resistance, in the treatment of ovarian cancer.

KW - Anticancer agents

KW - Constitutive androstane receptor

KW - Multiple drug resistance 1

KW - Ovarian cancer

KW - Uridine diphosphate-5′-glucuronosyltransferase 1A1

UR - http://www.scopus.com/inward/record.url?scp=84904656885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904656885&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2014.06.003

DO - 10.1016/j.bcp.2014.06.003

M3 - Article

C2 - 24928535

AN - SCOPUS:84904656885

VL - 90

SP - 356

EP - 366

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 4

ER -